Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 19/20 | 0.42 |
| ▸ | PRKDC | P78527 | 3/20 | 0.42 |
| ▸ | MTOR | P42345 | 13/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 13/20 | 0.37 |
| ▸ | ATR | Q13535 | 3/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.37 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29688033 | 1.00 | ATM (0.42) | ATMPRKDCMTORPIK3CAATR | |
| SCHEMBL23119283 | 0.90 | ATM (0.42) | ATMPRKDCMTORPIK3CAATR | |
| SCHEMBL29688251 | 0.90 | ATM (0.42) | ATMPRKDCMTORPIK3CAATR | |
| SCHEMBL29742730 | 0.90 | CTSS (0.41) | ATMPRKDCMTORPIK3CAATR | |
| SCHEMBL23119299 | 0.89 | ATM (0.54) | ATMPRKDCMTORPIK3CAATR | |
| SCHEMBL23119298 | 0.89 | ATM (0.54) | ATMPRKDCMTORPIK3CAATR | |
| SCHEMBL23093830 | 0.89 | ATM (0.54) | ATMPRKDCMTORPIK3CAATR | |
| SCHEMBL21541786 | 0.86 | ATM (0.51) | ATMPRKDCMTORPIK3CAATR | |
| SCHEMBL23119186 | 0.84 | ATM (0.49) | ATMPRKDCMTORPIK3CAATR | |
| SCHEMBL30192387 | 0.82 | ATM (0.39) | ATMPRKDCMTORPIK3CAATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021047646-A1 | SUBSTITUTED IMIDAZOQUINOXALINE COMPOUNDS AND USES THEREOF | IMPACT THERAPEUTICS, INC (CN) | 2021-03-18 | — | — | WO | disclosed |